Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 220 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NE[1eppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D4RlczKGh? M1nSbWROW09? MXTJR|UxRTBwMECwNFch|ryP NYWxNW97OTd7NU[wPFA>
K562 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXaO|IhcA>? NF62bm9FVVOR NFL3U|lKSzVyPUCuNFAyKM7:TR?= M3fISVE4QTV4MEiw
M07e M33PeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS3NkBp NWTvVYlTTE2VTx?= NYHxcpVrUUN3ME2wMlAxOTJizszN MmHzNVc6PTZyOEC=
ALL3 M1jO[GN6fG:2b4jpZ{BCe3OjeR?= NELnV4MxNjIQvF2= NV;RPHM4PzJiaB?= MofNSG1UVw>? NWnUb2pNUUN3ME2wMlAxODRizszN MljVNVk5QDl3NEC=
CML MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLsNlAhdWmw M2nGcGROW09? NXPJfmZLUUN3ME2wMlAxOSEQvF2= MnmyNVkzOTlyMU[=
BA/F3 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DFfFczKGh? MV7EUXNQ NFn5UJlKSzVyPU[uOVg6KM7:TR?= M{HXRVI{ODh6NkS0
BA/F3 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPrO|IhcA>? MVXEUXNQ M2nCU2lv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygUVM2OVRibYX0ZY51KHerdHigTWM2OCCxZjCwMlAxODh|zszN MUOyN|A5QDZ2NB?=
BA/F3 NIruXVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrs[lRRPzJiaB?= MUDEUXNQ MlziTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3Orbnege4lt\CC2eYDlJGJkei2DYnyge4l1cCCLQ{WwJI9nKDBwMEC0Oe69VQ>? M3v4VFI{ODh6NkS0
BA/F3 NEjTSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DUXFczKGh? NWjQSY5LTE2VTx?= MXvJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIGSzNVVKKG23dHHueEB4cXSqIFnDOVAhd2ZiMT63NVTPxE1? NVXJfWZGOjNyOEi2OFQ>
BA/F3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:3NkBp NXzkdpZITE2VTx?= M2\6SGlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEZ2OE\TJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFA6|ryP M{XhXlI{OzBzN{Cz
BA/F3 NGnZO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe3NkBp NXTRU4l{TE2VTx?= MnXBTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? NITBVI0zOzNyMUewNy=>
BA/F3 MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYm3NkBp M4fPe2ROW09? NULRU3g4UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiR{K1NGUhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxPTIQvF2= M1yyb|I{OzBzN{Cz
BA/F3 MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFi4T5M4OiCq M1TqSWROW09? MUXJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBSOjV{SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC4{txO M1O4VVI{OzBzN{Cz
BA/F3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;DOYM4OiCq NXTVV5M3TE2VTx?= MV;JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOzV7VjDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxN:69VQ>? NFjDNHQzOzNyMUewNy=>
BA/F3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3sXI84OiCq MmL4SG1UVw>? MV3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4Ppcochf2muZDD0fZBmKEKFUj3BRmwh[XO|ZYPz[YQh[XNiZ4Lve5RpKEmwaHnibZRqd25id3n0bEBKSzVyIH;mJFAvODBzOd88US=> MlHVNlM{ODF5MEO=
BA/F3 MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[2O|IhcA>? M3r1e2ROW09? NGHDW5pKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCC\MkWzTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAzO87:TR?= NHfselgzOzNyMUewNy=>
BA/F3 MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDPTHA4OiCq MoTaSG1UVw>? MVzJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> MX:yN|MxOTdyMx?=
BA/F3 NUDUUZFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVK3NkBp MmLsSG1UVw>? MW\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? MmfBNlM{ODF5MEO=
T cell Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3NkBp NV74NIxbTE2VTx?= Ml7rTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> NVXDOnNTOTdzNUS1NVI>
WiDr MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnHSmFCPzJiaB?= M2TsXGROW09? M3zHcGlEPTB;MD6wOVIh|ryP NWjRTIVEOTV4MUW1NVI>
PC3 NXvnOI1UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3hO|IhcA>? M2jxSWROW09? M1XqTWlEPTB;MD6wNFk1KM7:TR?= NVr3V3V4OTV4MUW1NVI>
MDA-MB-231 M13oUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLvO|IhcA>? MmHxSG1UVw>? MW\JR|UxRTBwMEGyJO69VQ>? NF\lW5MyPTZzNUWxNi=>
Hs578T MYjDfZRwfG:6aXOgRZN{[Xl? MWK3NkBp NUnwOmZpTE2VTx?= NHLKeIZIUTVyPUCuNFMh|ryP NFW4[YEzPDBzNUOyOy=>
HMEC NXnSdYxXS3m2b4TvfIlkKEG|c3H5 Mmf2O|IhcA>? MXTEUXNQ Mn7LS2k2OD1zLkig{txO NWrvSZU5OjRyMUWzNlc>
DU145 MljRR5l1d3SxeHnjJGF{e2G7 MUC3NkBp NFq3W25FVVOR MV3HTVUxRTBwMU[g{txO NYHGOWRzOjRyMUWzNlc>
U251 NGP6[Y5EgXSxdH;4bYMhSXO|YYm= MXy3NkBp M1TpbmROW09? NWnzVVVyT0l3ME2yMlgyKM7:TR?= MkfiNlQxOTV|Mke=
NCI60 MYnDfZRwfG:6aXOgRZN{[Xl? NH7CUVc4OiCq NInoNHZFVVOR MlnXS2k2OD13Lkeg{txO M2nMNFI1ODF3M{K3
MALME-3M M4rSdGN6fG:2b4jpZ{BCe3OjeR?= MmXDO|IhcA>? MXrEUXNQ NGDyRVVIUTVyPU[uOlEh|ryP NFHyWWEzPDBzNUOyOy=>
KM12 Mo\OR5l1d3SxeHnjJGF{e2G7 NHPiZpo4OiCq NWPxVVNITE2VTx?= NXfueVF6T0l3ME23MlQ1KM7:TR?= NEi4NlczPDBzNUOyOy=>
SW620 NYP0T4pRS3m2b4TvfIlkKEG|c3H5 MX63NkBp M{naVmROW09? MkTOS2k2OD16LkSzJO69VQ>? M{PH[|I1ODF3M{K3
RXF 393NL M2rXXWN6fG:2b4jpZ{BCe3OjeR?= MmPJOEBl[Xm| MnvMSG1UVw>? MVrJR|UxRTBwMEKxO{DPxE1? NHrvNVQzOzJ3M{C3OC=>
LXFA 983L NYqxOmZpS3m2b4TvfIlkKEG|c3H5 NGWydFg1KGSjeYO= MXXEUXNQ MnfvTWM2OD1yLkC1OlUh|ryP NWHOT|J4OjN{NUOwO|Q>
PRXF DU145 M1;3[2N6fG:2b4jpZ{BCe3OjeR?= NW\5OWFYPCCmYYnz Mk\nSG1UVw>? NVz5PJA5UUN3ME2wMlA3OjNizszN NHjjWXEzOzJ3M{C3OC=>
PAXF 1657L MnjVR5l1d3SxeHnjJGF{e2G7 M3XnU|Qh\GG7cx?= MoXJSG1UVw>? MlTZTWM2OD1yLkGyNUDPxE1? NFj2dowzOzJ3M{C3OC=>
CXF 1103L M3vtWmN6fG:2b4jpZ{BCe3OjeR?= MWC0JIRigXN? NYTKeXdWTE2VTx?= NHfFPGJKSzVyPUSuN|Yh|ryP MWCyN|I2OzB5NB?=
GXF251L MnK5R5l1d3SxeHnjJGF{e2G7 MUi0JIRigXN? Mlr4SG1UVw>? MWnJR|UxRTJwMkWg{txO NGPvR|czOzJ3M{C3OC=>
NCI-H23 NIHTb3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3OVczKGh? MmLYSG1UVw>? MljNTWM2OD1{LkK3JO69VQ>? MoLSNlM2OjFyMkC=
HCT116 NH7aXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU[3NkBp NX;jTFlVTE2VTx?= NISyOpZKSzVyPUKuN{DPxE1? NWD5U2NDOjN3MkGwNlA>
MCF7 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\zO|IhcA>? NWrSUpNNTE2VTx?= NWG5NFhTUUN3ME2yMlU4KM7:TR?= NEfIVmUzOzV{MUCyNC=>
NCI-H460 M3ryb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLzO|IhcA>? NFy0e4hFVVOR NHTRcHVKSzVyPUiuPVkh|ryP MXuyN|UzOTB{MB?=
DLD1 NHPxUotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPFc4ZWPzJiaB?= NXLnN2FpTE2VTx?= MoPWTWM2OD12Lk[g{txO NHvpUIIzOzV4N{m2NC=>
NCI-H661 MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETWT2E4OiCq NYHNWXBCTE2VTx?= MWXJR|UxRTdwODFOwG0> M{fEdFI{PTZ5OU[w
A549 M2Lmbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp MXrEUXNQ M33tUWlEPTB;OD6yJO69VQ>? NHjSR5YzOzV4N{m2NC=>
U937 NXu2[5hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG3NkBp NH7oVFhFVVOR NHrHNHFKSzVyPUGyMlIh|ryP NIPE[mUzOzV4N{m2NC=>
HEK293 NF\iXIdHfW6ldHnvckBCe3OjeR?= NY\mTGdqOTEEoN88US=> NHvMPVJFVVOR NH:ycXVKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> NYXnPGh6OjJ5N{C2NVA>
HUVEC M3;KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTG[2k{OC5zNdMg{txO M163eFczKGh? NF\6VJlFVVOR M2n5fWlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> MkPSNlI5PTN7OUO=
HUVEC MmDNSpVv[3Srb36gRZN{[Xl? Mn7INVXDqM7:TR?= NXXIOnFDPzJiaB?= M4LjTmROW09? NWXKeVh{UW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? M{XI[|IzQDV|OUmz
Plasmodium falciparum Mn3PSpVv[3Srb36gRZN{[Xl? MV2xNOKh|ryP MljNNVUhdWmw NV7HWXVMTE2VTx?= MV;Jcohq[mm2czDQcIF{dW:maYXtJIZidGOrcHHyeY0heHKxbHnm[ZJifGmxbjDifUBqdmirYnn0bY5oKHSqZTDGeY5kfGmxbjDv[kBR\kOGUFuxJJBzd3SnaX6ge4l1cCCLQ{WwJI9nKDFwMUhOwG0> MoPmNlQ2PTB|M{C=
PC3 M3;mVGZ2dmO2aX;uJGF{e2G7 MXuwMlEh|ryP NHLmdnE2KGh? NX7tZnVwTE2VTx?= MoTYTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P NGXJTpgyQTR4Mkm3OS=>
DU145 MYXGeY5kfGmxbjDBd5NigQ>? NEWxencxNjFizszN NEnzXJQ2KGh? NGDOWHJFVVOR M3nONmlvcGmkaYTzJIh2dWGwIFTVNVQ2KGOnbHygZYRp\XOrb36gZZQhOTByIH7N NGDXZ4cyQTR4Mkm3OS=>
PC3 MnTBT4lv[XOnIFHzd4F6 MV:wMlEh|ryP NX\wV45sPSCq Mnm5SG1UVw>? MkP3TY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= Mni5NVk1PjJ7N{W=
DU145 MX3LbY5ie2ViQYPzZZk> NIHERogxNjFizszN MXW1JIg> M4PGVGROW09? NHPLN4RKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> M2DnelE6PDZ{OUe1
PC3 M1uxO2tqdmG|ZTDBd5NigQ>? MVGwMlEh|ryP MX:1JIg> Mlu1SG1UVw>? MUDJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NUnjXXJtOTl2NkK5O|U>
DU145 MYDLbY5ie2ViQYPzZZk> NXiyTItVOC5zIN88US=> NFPUTGE2KGh? NE\0fHFFVVOR M1[zOGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NID3T|IyQTR4Mkm3OS=>
Huh7 NVjvT4NSSW62aY\pdoFtKEG|c3H5 NIC3XnEzNjVizszN NEXyZ3g1KGSjeYO= M1fBd2ROW09? M1viR2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= MVWxO|M3ODZ5Nh?=
C6/36 MVfBcpRqfmm{YXygRZN{[Xl? Mlr3Nk42KM7:TR?= NXLLdnBZPCCmYYnz M2XXXWROW09? M{XXbmlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? M1K1Z|E4OzZyNke2
U937 NG\wTlBHfW6ldHnvckBCe3OjeR?= MXqxJO69VQ>? NI[3N5IyKGh? MnPUSG1UVw>? NFSxdphT\WS3Y3XzJIJie2GuIGTOSoFteGijIILlcIVie2ViaX6gbJVu[W5iVUmzO{Bk\Wyucx?= NE\2VWEyPzZ6NEC5PS=>
U937 MUnGeY5kfGmxbjDBd5NigQ>? NH34W2UyKM7:TR?= NXLme5FDOSCq NI\ERmpFVVOR M3jQdXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ NGHXRYUyPzZ6NEC5PS=>
murine mast cell M1fpRmZ2dmO2aX;uJGF{e2G7 MkjNNUDPxE1? Ml;xNlQhcA>? M2PRXGROW09? M1v3UGlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP NW\xTGY6OTd4OESwPVk>
BV-173 M{nlcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHjSYlKSzVyPUCuNFAxODByMUC5JO69VQ>? Mmm1V2FPT0WU
K-562 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTBwMECwNFAxOjZ4IN88US=> MWrTRW5ITVJ?
BL-70 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlKwTWM2OD1yLkCwNFAxODh{MjFOwG0> NFm0fFZUSU6JRWK=
EM-2 NIrpW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHrToU2UUN3ME2wMlAxODByMUC4JO69VQ>? MYnTRW5ITVJ?
LAMA-84 NHK0e2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1i0eGlEPTB;MD6wNFAxODN{MTFOwG0> MmW5V2FPT0WU
MEG-01 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0WWpKSzVyPUCuNFAxODB7ODFOwG0> NVjXNYV6W0GQR1XS
EoL-1-cell MlHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17mNWlEPTB;MD6wNFAxOTNzIN88US=> M1nE[XNCVkeHUh?=
CTV-1 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n5UGlEPTB;MD6wNFAxPDB2IN88US=> M2LDO3NCVkeHUh?=
TE-15 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTDTWM2OD1yLkCwOVg6KM7:TR?= Moi4V2FPT0WU
NOS-1 MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnTTWM2OD1yLkCwOlE{KM7:TR?= M4fkWXNCVkeHUh?=
D-336MG Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXleoZiUUN3ME2wMlAxPjNizszN MVjTRW5ITVJ?
LB1047-RCC NXXESWwxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHjUI1RUUN3ME2wMlAxQTh7IN88US=> MkXmV2FPT0WU
LB996-RCC Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWzSnZKSzVyPUCuNFA6QTFizszN M2fJWHNCVkeHUh?=
SW982 NVTC[HF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTkVYN[UUN3ME2wMlAyOTF3IN88US=> NYr0d|A2W0GQR1XS
TK10 NUP4V45GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2L0OmlEPTB;MD6wNVE4PCEQvF2= M1POOHNCVkeHUh?=
A704 NFThT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TMOWlEPTB;MD6wNVQ6OSEQvF2= M3fROXNCVkeHUh?=
TE-8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;VTWM2OD1yLkCxOVc3KM7:TR?= M3LuNXNCVkeHUh?=
DOHH-2 NETl[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O5T2lEPTB;MD6wNVcyQSEQvF2= MnzlV2FPT0WU
HOP-62 NGSwRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEG4N|Qh|ryP NVn0VIdjW0GQR1XS
TE-12 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnzVI1KSzVyPUCuNFE5PjFizszN MYLTRW5ITVJ?
KGN MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwMEG5OFIh|ryP M3rkbnNCVkeHUh?=
NCI-H1648 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PkTWlEPTB;MD6wNlAyOSEQvF2= NYjCRlJqW0GQR1XS
OS-RC-2 NETaZoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn3XHB6UUN3ME2wMlAzODNizszN NWDUOYRnW0GQR1XS
GB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTCe5IzUUN3ME2wMlAzOTV5IN88US=> M{DFfXNCVkeHUh?=
RXF393 NHnPb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17PSmlEPTB;MD6wNlM2PyEQvF2= MofiV2FPT0WU
LC-2-ad MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMEK1PFYh|ryP MWfTRW5ITVJ?
KS-1 NF7sbHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHRbHpKSzVyPUCuNFI4OyEQvF2= NXXtSYFJW0GQR1XS
ETK-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEK4N|Ih|ryP NFnDVWVUSU6JRWK=
SW954 NXHyO4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy2RmNiUUN3ME2wMlAzQTJ5IN88US=> NX7UNYg2W0GQR1XS
Becker MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrQTppKSzVyPUCuNFMxODNizszN M16yW3NCVkeHUh?=
MZ1-PC NHjQZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DuUmlEPTB;MD6wN|EyQSEQvF2= NYqxdYR3W0GQR1XS
ES6 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLIXpJjUUN3ME2wMlA{OTl|IN88US=> MnL1V2FPT0WU
KURAMOCHI NHWwW|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOdmlEPTB;MD6wN|Q5PyEQvF2= M2PCZ3NCVkeHUh?=
CGTH-W-1 NWnSTGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fSdGlEPTB;MD6wN|U1QCEQvF2= M2PofnNCVkeHUh?=
VA-ES-BJ NX[zNGh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfHb5lkUUN3ME2wMlA{QTB{IN88US=> MYjTRW5ITVJ?
LXF-289 M1nmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEO5OVYh|ryP NHW4XWNUSU6JRWK=
MPP-89 M{f1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUOyTpUxUUN3ME2wMlA1ODR7IN88US=> NGewW4NUSU6JRWK=
SW872 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\zTlNKSzVyPUCuNFQyPjFizszN NWDxT|BNW0GQR1XS
SNB75 M3LsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTkTWM2OD1yLkC0OFM2KM7:TR?= NUfVbY83W0GQR1XS
PSN1 M1jscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37GeGlEPTB;MD6wOFQ4PCEQvF2= MWnTRW5ITVJ?
LB831-BLC NHLXZnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjmTWM2OD1yLkC0OlA6KM7:TR?= MYHTRW5ITVJ?
MFH-ino NVTHXmk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMES3NlQh|ryP NI\KVZFUSU6JRWK=
TGBC24TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMES3OlEh|ryP NHu1NWxUSU6JRWK=
A388 NWDtNog2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETTTo9KSzVyPUCuNFUxQTVizszN MlLoV2FPT0WU
BB30-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDOTWM2OD1yLkC1OFM4KM7:TR?= NYDjRnpRW0GQR1XS
GI-ME-N NYnhSGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4faZ2lEPTB;MD6wOlEyQCEQvF2= MlnOV2FPT0WU
TGBC1TKB MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf2NYd4UUN3ME2wMlA3OTZ2IN88US=> MlrXV2FPT0WU
TE-10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LGTWlEPTB;MD6wOlM2PyEQvF2= MmK2V2FPT0WU
A498 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjhTWM2OD1yLkC3Nlg1KM7:TR?= NXTOSnpxW0GQR1XS
TE-11 MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn31TWM2OD1yLkC3PFU5KM7:TR?= MYDTRW5ITVJ?
BB65-RCC M1OwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLhTWM2OD1yLkC4NlI4KM7:TR?= MUnTRW5ITVJ?
C2BBe1 M3PNSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP1[XhbUUN3ME2wMlA5OzB6IN88US=> M4LpVHNCVkeHUh?=
NCI-H747 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEizOlIh|ryP M1HnU3NCVkeHUh?=
IST-MES1 M33KOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPJfZVKSzVyPUCuNFg2PTJizszN NELscWJUSU6JRWK=
KALS-1 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW1fJo1UUN3ME2wMlA6PDlizszN M4L6ZnNCVkeHUh?=
GCIY NWfse41oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXjTWM2OD1yLkC5OlU3KM7:TR?= NITqfphUSU6JRWK=
RL95-2 NF[yeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n6[GlEPTB;MD6xNFM5KM7:TR?= M2i5bHNCVkeHUh?=
TE-1 NFz3bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfNNJhKSzVyPUCuNVA2PCEQvF2= Mmq5V2FPT0WU
NCI-H1355 NIDXVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMUGwNlgh|ryP NXnEXYc5W0GQR1XS
SW962 Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfP[2poUUN3ME2wMlEyOjl{IN88US=> M4j6TnNCVkeHUh?=
KLE MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF24WVlKSzVyPUCuNVE{OTdizszN MkfGV2FPT0WU
MC116 NGCydoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqzTWM2OD1yLkGxOFEh|ryP NEf5dZVUSU6JRWK=
NMC-G1 NF3Dd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXFTWM2OD1yLkGxOlA3KM7:TR?= NUnSS|V4W0GQR1XS
KU812 MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDtTWM2OD1yLkGxPFg{KM7:TR?= NF7jbZpUSU6JRWK=
COLO-829 NV6zclY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMUKyNVMh|ryP NXfLPFlmW0GQR1XS
NTERA-S-cl-D1 NHH5eXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7hTWM2OD1yLkGyNlg{KM7:TR?= NFr3[2NUSU6JRWK=
IST-MEL1 NF;qbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTBwMUO0OUDPxE1? M13YV3NCVkeHUh?=
MLMA MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknmTWM2OD1yLkG0NFMzKM7:TR?= MV;TRW5ITVJ?
LS-123 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUSwOlQh|ryP NIPRW4tUSU6JRWK=
LB2518-MEL NV\6NYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXVTWM2OD1yLkG0NVYzKM7:TR?= NGHuO5VUSU6JRWK=
NB69 MkGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMUS0N|Yh|ryP NUO3RWpPW0GQR1XS
8-MG-BA NEmxb|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnKTWM2OD1yLkG1OFU5KM7:TR?= M4S0dHNCVkeHUh?=
K5 M33WOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMU[0PFkh|ryP NHXhTHNUSU6JRWK=
KINGS-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTYdWVvUUN3ME2wMlE3PjZ4IN88US=> MV3TRW5ITVJ?
SF268 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLKe2p2UUN3ME2wMlE4PDB2IN88US=> NXK0cGtzW0GQR1XS
PF-382 MkjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\TZYRKUUN3ME2wMlE4Pjd6IN88US=> NEjWcXNUSU6JRWK=
SH-4 M2j3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3IO3lKSzVyPUCuNVg1OTNizszN NGPV[5ZUSU6JRWK=
NALM-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\KOXpiUUN3ME2wMlE6Ojl3IN88US=> MnvkV2FPT0WU
CP66-MEL NYOzS3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTE[VBKSzVyPUCuNVk2OzFizszN M{fmcXNCVkeHUh?=
697 M4n1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHETWM2OD1yLkG5PVg4KM7:TR?= NFuyXXFUSU6JRWK=
CP67-MEL Mn:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX4b2JKSzVyPUCuNlA1QDhizszN NFnVRlhUSU6JRWK=
DSH1 NFfa[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz4OY9KSzVyPUCuNlQxODFizszN NWnJPXZ6W0GQR1XS
HCE-4 NV\DS4dZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPUUok5UUN3ME2wMlI3PDN7IN88US=> Mly3V2FPT0WU
MZ2-MEL Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HVSmlEPTB;MD6yPFU{PyEQvF2= M4\zVnNCVkeHUh?=
BL-41 NIWzUG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTZTWM2OD1yLkK5NVI{KM7:TR?= NF\ZOmVUSU6JRWK=
HUTU-80 NEnVV25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwM{G0NkDPxE1? NUnVPVRTW0GQR1XS
LOXIMVI NFPke3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fsbmlEPTB;MD6zNVUxOyEQvF2= Mmm3V2FPT0WU
no-10 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf1OpBKSzVyPUCuN|E6OzFizszN MYfTRW5ITVJ?
KARPAS-422 M2\0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zoPGlEPTB;MD6zN|k6PyEQvF2= MkL4V2FPT0WU
SW684 NXr3SGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\FTVJKSzVyPUCuN|Q6QCEQvF2= NYPU[4l1W0GQR1XS
SF126 MoHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3X1O2lEPTB;MD6zOVQyKM7:TR?= NELzPZdUSU6JRWK=
D-263MG NVS1fotyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPXeXc5UUN3ME2wMlM3OjJ2IN88US=> MnrBV2FPT0WU
OVCAR-4 NEPNfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[5NGlEPTB;MD6zO|Q{OyEQvF2= NEHpS2VUSU6JRWK=
BB49-HNC M2PEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\NRWlEPTB;MD6zPFU6QSEQvF2= M{fNOnNCVkeHUh?=
ONS-76 NUDNVGZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNEK5OVEh|ryP MlzLV2FPT0WU
MZ7-mel MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1T5emlEPTB;MD60O|kyOSEQvF2= NW[1c2IxW0GQR1XS
RCC10RGB NHLRbGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDHbIJFUUN3ME2wMlQ6OTFizszN M3T6XHNCVkeHUh?=
BOKU NEnSUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n4OmlEPTB;MD60PVE{OyEQvF2= MkjkV2FPT0WU
no-11 NIjjVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvYTWM2OD1yLkWwNlI5KM7:TR?= MXHTRW5ITVJ?
IST-SL2 MnHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\NRmlEPTB;MD61NFMxOiEQvF2= M365bnNCVkeHUh?=
RKO Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LUSGlEPTB;MD61Nlk3PiEQvF2= MonwV2FPT0WU
HT-144 NF3rXZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrsPXpKSzVyPUCuOVM3ODlizszN Mli1V2FPT0WU
NCI-H446 Ml\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXMTWM2OD1yLk[yO|Yh|ryP MXLTRW5ITVJ?
QIMR-WIL NU\GOJhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vzUGlEPTB;MD63NFYzQSEQvF2= NUDEOY9XW0GQR1XS
MHH-PREB-1 M2XJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmydI5XUUN3ME2wMlc1PDZ7IN88US=> M4fm[XNCVkeHUh?=
EW-16 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwN{[xO|gh|ryP MU\TRW5ITVJ?
EW-24 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LMVmlEPTB;MD63PFE3PSEQvF2= M4fae3NCVkeHUh?=
LB373-MEL-D NW\jVHMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwOEK1NFgh|ryP NVq1R45rW0GQR1XS
TE-9 NXS1VI1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLrRZJKSzVyPUCuPFc2OzJizszN NXLzVpM5W0GQR1XS
A3-KAW NFTMS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLQdnBQUUN3ME2wMlk5PDV{IN88US=> M3fwZ3NCVkeHUh?=
A101D MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnDXFI2UUN3ME2xMlA{ODR|IN88US=> MVjTRW5ITVJ?
OCUB-M M4HnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz0OIV[UUN3ME2xMlA1PDF{IN88US=> NWqzemxiW0GQR1XS
ES4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\zXGlEPTB;MT6wOVE1PSEQvF2= Mn3WV2FPT0WU
TE-6 NYmzNWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L5SWlEPTB;MT6yNVIzPiEQvF2= NFrtWHJUSU6JRWK=
D-502MG NWPwboFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\BTWM2OD1zLkKzN|c3KM7:TR?= NIm3NGxUSU6JRWK=
KNS-42 NWj5PVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwMkS0NVIh|ryP MV;TRW5ITVJ?
SNU-C2B MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrwXXBKSzVyPUGuN|A2QDlizszN NEj3OIZUSU6JRWK=
NCI-H1838 M4m5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwM{C3N|Mh|ryP Ml7kV2FPT0WU
NKM-1 M4r2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i1ZWlEPTB;MT6zNFg2QSEQvF2= M3HRRXNCVkeHUh?=
GI-1 NHvOd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHJWG9KSzVyPUGuN|YzOiEQvF2= NHzvdFFUSU6JRWK=
NB5 NWDVbpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXuPZBKSzVyPUGuN|k5OjdizszN MoP4V2FPT0WU
CAS-1 NY\hRWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jkRmlEPTB;MT60NFk6OiEQvF2= MUDTRW5ITVJ?
HCE-T M1LsO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\GVWlEPTB;MT61OlcyPCEQvF2= NXLHbZNjW0GQR1XS
SBC-1 NFLrZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DBcmlEPTB;MT61O|k5PCEQvF2= NFLOeJRUSU6JRWK=
JiyoyeP-2003 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPpPY9KSzVyPUGuO|M1PjZizszN M3vUV3NCVkeHUh?=
TE-5 NIm3d|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4myRWlEPTB;MT63PVE{QSEQvF2= M3LWOXNCVkeHUh?=
CAN MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnFWXl7UUN3ME2xMlgzOjV{IN88US=> M17jUnNCVkeHUh?=
SK-UT-1 M{\3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHSTWM2OD1{LkG2Olk{KM7:TR?= Mof0V2FPT0WU
JVM-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfte4xKSzVyPUKuN|YzQDRizszN M4DhSXNCVkeHUh?=
LB771-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXZboF5UUN3ME2yMlU4PTVzIN88US=> M{nhR3NCVkeHUh?=
NCCIT Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX1RYJKSzVyPUKuPFY3OTZizszN NETL[GtUSU6JRWK=
NCI-H2126 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[yTllNUUN3ME2yMlg4PTV{IN88US=> M{DMWnNCVkeHUh?=
Calu-6 NWjJeoIxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rz[GlEPTB;Mz6wOVc1OSEQvF2= M3y3NHNCVkeHUh?=
SK-LMS-1 NHnSfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf5TWM2OD1|LkGxPFg3KM7:TR?= Ml35V2FPT0WU
ARH-77 M2juPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjSPFY3UUN3ME2zMlQ3QTF3IN88US=> M3HyTXNCVkeHUh?=
NB17 M{m0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W4OmlEPTB;Mz62N|g1PyEQvF2= M2jmOXNCVkeHUh?=
A253 MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\kR4RKSzVyPUOuO|MzPDZizszN M3W4enNCVkeHUh?=
OPM-2 NU[wOI5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTRwMke2PFUh|ryP NXHhTlJ1W0GQR1XS
MV-4-11 NUTGSpc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTRwM{[0OVQh|ryP NWK1PIl[W0GQR1XS
SR M{n3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnv2TWM2OD12LkS5PVU1KM7:TR?= MUTTRW5ITVJ?
KG-1 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDOTWM2OD12Lk[wPFQ2KM7:TR?= NV;ZW4cyW0GQR1XS
OCI-AML2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXFU4dKSzVyPUWuPFYyPTRizszN NGnwblhUSU6JRWK=
D-247MG NGjWOWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\IPIU3UUN3ME22MlEzPTF7IN88US=> MUDTRW5ITVJ?
DJM-1 Mn3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIT4SG1KSzVyPU[uOFg2PThizszN Mkj3V2FPT0WU
RPMI-6666 NVGwfIp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu3c49{UUN3ME23MlI4ODZ5IN88US=> NXfWR4RnW0GQR1XS
KARPAS-45 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTdwNUG2O|Eh|ryP M2DsXHNCVkeHUh?=
LP-1 NH\NdXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnM[5FIUUN3ME23MlU1Pzh{IN88US=> MV;TRW5ITVJ?
RS4-11 NEnLdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n4bmlEPTB;Nz62OVc5PyEQvF2= NW\GbGhuW0GQR1XS
DU-4475 MlLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PzRWlEPTB;OD6yNVY2OiEQvF2= NYX4TZdRW0GQR1XS
MONO-MAC-6 NGC2ZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\UTWM2OD16LkK3NFY3KM7:TR?= MXrTRW5ITVJ?
NCI-SNU-16 NH\wSpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\ROJRxUUN3ME24MlU3OTJ6IN88US=> M1vsOXNCVkeHUh?=
SJSA-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHIRYtKSzVyPUiuO|I5ODVizszN NEHjeVZUSU6JRWK=
MMAC-SF MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRThwN{mzNFch|ryP NWr2dpJwW0GQR1XS
SK-NEP-1 NGHZcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXoSoNKSzVyPUiuPFkyPTVizszN NYHxPFhzW0GQR1XS
J-RT3-T3-5 NFTycmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDnTWM2OD16Lkm2OVI6KM7:TR?= MmLuV2FPT0WU
SKM-1 NXi2[mViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjyU2lVUUN3ME25MlAyPzN2IN88US=> MX\TRW5ITVJ?
LB2241-RCC NYDwcVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jBfWlEPTB;OT6wNlAyOiEQvF2= NW\HdWZiW0GQR1XS
SIG-M5 NHTnR5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHq4[lhKSzVyPUmuNFI1QTNizszN NWP6dHpFW0GQR1XS
EVSA-T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlWyTWM2OD17LkK3O|k{KM7:TR?= MUnTRW5ITVJ?
GT3TKB NX7CVlJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGOzcXpKSzVyPUmuN|U2PDZizszN NUT3enVEW0GQR1XS
NB6 NETyfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTlwOUKyOVkh|ryP NX:zSmRwW0GQR1XS
EHEB MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzITWM2OD1zMD6wOlU3KM7:TR?= M4TxZnNCVkeHUh?=
HEL M3jQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPxTWM2OD1zMD60O|c3KM7:TR?= M3\pUHNCVkeHUh?=
ALL-PO MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTFyLke5N|gh|ryP MojxV2FPT0WU
TGW MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD6TWM2OD1zMT6yPFI5KM7:TR?= MnrHV2FPT0WU
BC-3 M4TEOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XMZWlEPTB;MUKuNVE{QCEQvF2= NVHpVGY6W0GQR1XS
IA-LM MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:5OodlUUN3ME2xNk41PDR3IN88US=> NUnGUlZsW0GQR1XS
UACC-257 M2nFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF{LkmxPVgh|ryP M2PCT3NCVkeHUh?=
KP-N-YS NXjDNlU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LRb2lEPTB;MUKuPVI5OyEQvF2= NYjvcoNmW0GQR1XS
Raji NVjGbHl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTF|Lke0PVch|ryP M1;xWHNCVkeHUh?=
SF539 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr1d4tKSzVyPUGzMlg2PTdizszN NXLDSohXW0GQR1XS
DMS-153 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF2LkCwNlgh|ryP Mmf2V2FPT0WU
L-540 NYXrSppjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF3LkC2O|Ih|ryP MWjTRW5ITVJ?
MN-60 NFvQZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrmTWM2OD1zNT6xPVc6KM7:TR?= M{PUdXNCVkeHUh?=
RPMI-8866 NUfySItjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfhcIRlUUN3ME2xO{41PDV2IN88US=> Mkn1V2FPT0WU
NCI-H510A NYL6NolWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzR[lZKSzVyPUG5MlM6PzNizszN NFPGfZBUSU6JRWK=
NB13 M4XodGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTF7LkS4O|ch|ryP Mn7PV2FPT0WU
HAL-01 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2wTWM2OD1zOT63OVQ{KM7:TR?= NV21dW4{W0GQR1XS
NCI-H720 NEn3Zo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm0TWM2OD1{MD6yO|M{KM7:TR?= NU\yPXlUW0GQR1XS
REH Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJyLk[zOVch|ryP NWPPS49TW0GQR1XS
KNS-81-FD Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj5TWM2OD1{Mz6xOFYh|ryP MlTxV2FPT0WU
HC-1 MkPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzGTWw{UUN3ME2yOE42PTVzIN88US=> MVLTRW5ITVJ?
NCI-H2141 NVPSXW52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHmS|lKSzVyPUK0Mlc4PTRizszN NV7Vd2JJW0GQR1XS
MOLT-4 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\3TWM2OD1{Nj62O|U{KM7:TR?= MnvZV2FPT0WU
OMC-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjiXZFNUUN3ME2yO{4yPDJ{IN88US=> M4[1UXNCVkeHUh?=
LC-1F NVfSXmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfxfHhqUUN3ME2yO{4{OjR3IN88US=> NXPzUpYyW0GQR1XS
NCI-H1304 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDQTWM2OD1{OD6xOlI5KM7:TR?= NVHMflBPW0GQR1XS
BC-1 Mmn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPYTWM2OD1{OD62OVEh|ryP NV\uWpJpW0GQR1XS
NCI-H64 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnryTWM2OD1{OT62NlU{KM7:TR?= MVjTRW5ITVJ?
MOLT-16 MmDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLXTWM2OD1{OT62NlkzKM7:TR?= NY\yOlVpW0GQR1XS
U-87-MG NW\pe5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNyLke2OkDPxE1? MoDZV2FPT0WU
GAK MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6xZ3VIUUN3ME2zNU4zPjh4IN88US=> Moq4V2FPT0WU
ES8 M2na[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjnPWhKUUN3ME2zNk4yOjV{IN88US=> MmDVV2FPT0WU
HCC1599 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTN{LkOzNlUh|ryP M2PKVHNCVkeHUh?=
EB-3 NVf6cm9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13qUGlEPTB;M{SuN|EyPyEQvF2= NF;iU49USU6JRWK=
HCC1187 NFPN[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPpVVd5UUN3ME2zOU45ODV{IN88US=> M3XZfHNCVkeHUh?=
SK-PN-DW MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfXUlAzUUN3ME2zOk4yQTR|IN88US=> NELHUHFUSU6JRWK=
JVM-3 NY\rV45sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTOSmNYUUN3ME2zO{4zOzN6IN88US=> NWPVdXFOW0GQR1XS
HCC2157 M2TzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTQTWM2OD1|Nz65PVQ3KM7:TR?= NHHNNXhUSU6JRWK=
A4-Fuk MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfiPG5DUUN3ME2zPE4yODB7IN88US=> MmjpV2FPT0WU
COR-L279 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD6TWM2OD12MD6yPFUyKM7:TR?= NF;KWmRUSU6JRWK=
DEL Mk\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6enVJUUN3ME20NU46ODh4IN88US=> M{nhWnNCVkeHUh?=
NCI-H1395 NFnGNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fmfWlEPTB;NEKuNFE3OyEQvF2= MmfRV2FPT0WU
MHH-NB-11 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPXb2dlUUN3ME20N{4xQDF6IN88US=> NFWxSZVUSU6JRWK=
NCI-H2107 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HGemlEPTB;NEOuOFg1PiEQvF2= NEDG[pdUSU6JRWK=
NEC8 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvzWlhKSzVyPUS0MlM{PiEQvF2= NGD2SZZUSU6JRWK=
COLO-684 NWLRV|J1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzUW291UUN3ME20Ok4zOjV6IN88US=> MXfTRW5ITVJ?
LS-411N MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i3UGlEPTB;NEiuOFc1QCEQvF2= M133W3NCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

- Collapse

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

- Collapse
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

- Collapse
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Not yet recruiting Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic December 2019 Phase 1|Phase 2
NCT04115059 Not yet recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2
NCT03193281 Recruiting Drug: Dasatinib|Drug: Imatinib Chronic Myeloid Leukemia University of Auckland New Zealand|Leukaemia & Blood Cancer New Zealand July 17 2017 Phase 2
NCT03041701 Recruiting Drug: Dasatinib|Drug: Ganitumab Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID